EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudie

Cefiderocol-containing regimens versus best available therapy for carbapenem-resistant Acinetobacter infections

Madeline Murphy, Punit J Shah, Meghan Thibeaux

American Journal of Health-System Pharmacy · 2025

DOI: 10.1093/ajhp/zxaf189 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift American Journal of Health-System Pharmacy, 2025. Verfasst von Madeline Murphy und 2 weiteren Autor:innen. Beteiligte Einrichtung: Houston Methodist Hospital, Houston, TX, USA. Hauptthemen laut MEDLINE: Acinetobacter Infections, Anti-Bacterial Agents, Carbapenems, Cefiderocol. Die Arbeit nennt 8 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Carbapenem-resistant Acinetobacter baumannii (CRAB) poses an urgent therapeutic challenge worldwide as there are few treatment options available. Cefiderocol is a novel siderophore cephalosporin that has shown potent in vitro activity against A. baumannii. Published literature on the clinical use of cefiderocol for management of CRAB infections is limited with contradictory findings, contributing to a lack of consensus on optimal treatment regimens for CRAB. The objective of this study was to compare mortality in patients treated with cefiderocol-containing regimens versus best available therapy (BAT) for infections caused by CRAB.

Methods

This was a multicenter, retrospective, cohort study conducted from November 2021 through June 2023. Adult patients with CRAB infections confirmed by isolation of CRAB who received at least 48 hours of treatment active against CRAB were included. Patients with CRAB isolated from a urinary source or concomitant gram-positive bacteremia or fungemia were excluded. The primary outcome was inpatient mortality or discharge to hospice.

Results

Baseline characteristics were similar between the two groups except that more patients who received cefiderocol-containing regimens had bacteremia (21% vs 6%; P = 0.015, 95% CI, 0.02-0.28) and were on vasopressors (42% vs 19%; P = 0.011, 95% CI, 0.05-0.38). Patients with a CRAB infection treated with a cefiderocol-containing regimen had a statistically significant higher rate of inpatient mortality or discharge to hospice when compared to the BAT group (36% vs 14%; difference, 0.2 [95% CI, 0.06-0.38]; P = 0.005).

Conclusion

Patients treated with cefiderocol-containing regimens had a higher rate of inpatient mortality or discharge to hospice than those who received BAT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acinetobacter InfectionsAnti-Bacterial AgentsCarbapenemsCefiderocolAcinetobacter baumanniiCephalosporinsHumansMaleRetrospective StudiesFemaleAgedMiddle AgedCohort StudiesAged, 80 and over

Stichwörter der Autor:innen

CRABcarbapenem-resistant Acinetobacter baumanniicefiderocol

Substanzen

Anti-Bacterial AgentsCarbapenemsCefiderocolCephalosporins

Autor:innen und Institutionen

  • Houston Methodist Hospital, Houston, TX, USA.
  • Houston Methodist Sugar Land Hospital, Sugar Land, TX, USA.

Zitieren

APA

Murphy, M., Shah, P. J., & Thibeaux, M. (2025). Cefiderocol-containing regimens versus best available therapy for carbapenem-resistant Acinetobacter infections. American Journal of Health-System Pharmacy. https://doi.org/10.1093/ajhp/zxaf189

Vancouver

Murphy M, Shah PJ, Thibeaux M. Cefiderocol-containing regimens versus best available therapy for carbapenem-resistant Acinetobacter infections. American Journal of Health-System Pharmacy. 2025. doi:10.1093/ajhp/zxaf189

BibTeX
@article{Murphy2025,
  author = {Murphy, Madeline and Shah, Punit J and Thibeaux, Meghan},
  title = {Cefiderocol-containing regimens versus best available therapy for carbapenem-resistant Acinetobacter infections},
  journal = {American Journal of Health-System Pharmacy},
  year = {2025},
  doi = {10.1093/ajhp/zxaf189}
}
Kostenlos starten →